GENB (Generate Biomedicines) Revenue: $ Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

GENB Generate Biomedicines Inc GENB
6 GF Score
Price $14.39
! 1 Warning Sign
View Full Analysis

What is Generate Biomedicines Revenue?

Generate Biomedicines GENB +5.96% 6 Revenue is $ Mil as of Dec. 2025. GuruFocus rates GENB with a GF Score™ of 6/100. The stock has 1 warning sign investors should review.

Generate Biomedicines's revenue for the six months ended in Dec. 2025 was $31.89 Mil. Generate Biomedicines does not have enough years/quarters to calculate its revenue for the trailing twelve months (TTM) ended in Dec. 2025. Generate Biomedicines's Revenue per Share for the six months ended in Dec. 2025 was $0.31. Generate Biomedicines does not have enough years/quarters to calculate its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025.

During the past 12 months, the average Revenue per Share Growth Rate of Generate Biomedicines was 56.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

Generate Biomedicines  (NAS:GENB) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.

Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.

Generate Biomedicines Revenue Related Terms

Generate Biomedicines Revenue Historical Data

* Premium members only.

The historical data trend for Generate Biomedicines's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Generate Biomedicines Revenue Chart

Generate Biomedicines Annual Data
Trend Dec24 Dec25
Revenue
20.46 31.89

Generate Biomedicines Semi-Annual Data
Dec24 Dec25
Revenue 20.46 31.89

GENB vs PVLA, SLBT, NKTR: Revenue Comparison

For the Biotechnology subindustry, Generate Biomedicines's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Generate Biomedicines Revenue vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Generate Biomedicines's Revenue distribution charts can be found below:

* The bar in red indicates where Generate Biomedicines's Revenue falls into.


GENB
6GF Score
Generate Biomedicines Inc GENB
Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Generate Biomedicines Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Frequently Asked Questions Learn more about Revenue →
What does a Revenue of $ Mil mean?
Generate Biomedicines (GENB) has a Revenue of $ Mil as of Dec. 2025. Revenue is the total amount a company generates as sales through its operations. View historical data on Generate Biomedicines and its competitors.
Is Generate Biomedicines' Revenue too high?
Generate Biomedicines' current Revenue is $ Mil. Overall, Generate Biomedicines has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does Generate Biomedicines' Revenue compare to PVLA and SLBT?
Generate Biomedicines' Revenue of $ Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Biotechnology company?
A good Revenue depends on the Biotechnology industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Generate Biomedicines and its competitors. Generate Biomedicines's current Revenue is $ Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Generate Biomedicines stock overvalued right now?
Generate Biomedicines (GENB) has a current Revenue of $ Mil. The current Revenue is $ Mil. Generate Biomedicines' overall GF Score™ is 6/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Generate Biomedicines (GENB), the current Revenue is $ Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Generate Biomedicines Business Description

Address 101 South Street, Suite 900, Somerville, MA, USA, 02143
Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.
6GF Score

Get the complete analysis for GENB

Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$14.39
Price